stockrowACADIA Pharmaceuticals Inc.
ACAD Healthcare Biotechnology
ACADIA Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 11.9% from fiscal 2024.
- Revenue
- +22.9%
- EPS
- −27.9%
- Free cash flow
- +141.2%
Quarter to September 2026, against a year earlier
Follow ACAD
Alert me
ACADIA Pharmaceuticals Inc. (ACAD) Free cash flow margin
ACADIA Pharmaceuticals Inc.'s free cash flow margin over the twelve months to 30 September 2026 was 6.82%, down 3.0 percentage points from fiscal 2025 (9.81%). Over the past ten years it has ranged from −203,173.8% (fiscal 2015) to 16.4% (fiscal 2024); the current reading is higher than 91% of that period. That is above the Biotechnology industry median of 0.00% and above the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | 9.81% | (6.60) |
| FY2024 | 16.4% | 19.62 |
| FY2023 | −3.21% | 18.84 |
| FY2022 | −22.1% | 4.14 |
| FY2021 | −26.2% | 6.35 |
| FY2020 | −32.5% | 12.36 |
| FY2019 | −44.9% | 30.87 |
| FY2018 | −75.8% | 99.22 |
| FY2017 | −175.0% | 1,082.38 |
| FY2016 | −1,257.4% | 201,916.40 |
Against its own ten years
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. | 6.82% |
| XENE Xenon Pharmaceuticals Inc. compare | 0.00% |
| DYN Dyne Therapeutics, Inc. compare | 0.00% |
| IRON Disc Medicine, Inc. compare | 0.00% |
| PBLS Parabilis Medicines, Inc. compare | 0.00% |
| TNGX Tango Therapeutics, Inc. compare | 0.00% |
| VKTX Viking Therapeutics, Inc. compare | 0.00% |
| IOVA Iovance Biotherapeutics, Inc. compare | −57.0% |
| RLAY Relay Therapeutics, Inc. compare | −1,924.6% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on ACAD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement